Compare Pfizer Inc (PFE) vs Royal Bank of Canada (RY) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Royal Bank of Canada (RY) trades at $210.88, down 2.11% on the day, amid a bullish technical setup with support near $208 and resistance at $214. The company reported strong Q1 2026 earnings of $2.84 per share, beating estimates, and has a history of recent beats. Revenue grew to $66.53B in 2025, with a net income margin of 31.85% and a solid ROE of 17.17%. Analyst sentiment is mixed but leans positive, with a 43% buy rating.

RY's outlook is supported by consistent earnings performance and a robust dividend, recently increased to $1.76 per share. However, risks include elevated valuation multiples like a P/E of 19.42 and macroeconomic sensitivity. The stock offers stability through its banking diversification but faces headwinds from interest rate volatility and credit quality concerns.